479
Participants
Start Date
October 31, 2014
Primary Completion Date
July 31, 2016
Study Completion Date
July 31, 2016
MF59
Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
Duke Human Vaccine Institute - Duke Clinical Vaccine Unit, Durham
Emory Vaccine Center - The Hope Clinic, Decatur
University of Iowa - Vaccine Research and Education Unit, Iowa City
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore
Saint Louis University - Center for Vaccine Development, St Louis
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati
Vanderbilt University Medical Center - Vanderbilt Institute for Clinical and Translational Research - Clinical Research Center (VICTR-CRC), Nashville
University of Texas Medical Branch - Sealy Center for Vaccine Development - Clinical Trials Group, Galveston
Baylor College of Medicine - Molecular Virology and Microbiology, Houston
Group Health Research Institute - Seattle - Vaccines and Infectious Diseases, Seattle
National Institute of Allergy and Infectious Diseases (NIAID)
NIH